Study #2023-0087
A phase II study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-cell Therapy, in combination with radiotherapy (RT) in relapsed/refractory follicular lymphoma.
MD Anderson Study Status
Enrolling
Treatment Agent
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate, Prednisone, Diphenhydramine, Acetaminophen
Description
To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Follicular Lymphoma
Study phase:
Phase II
Physician name:
Susan Wu
Department:
Radiation Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.